Literature DB >> 24450889

A trial of mass isoniazid preventive therapy for tuberculosis control.

Gavin J Churchyard1, Katherine L Fielding, James J Lewis, Leonie Coetzee, Elizabeth L Corbett, Peter Godfrey-Faussett, Richard J Hayes, Richard E Chaisson, Alison D Grant.   

Abstract

BACKGROUND: Tuberculosis is epidemic among workers in South African gold mines. We evaluated an intervention to interrupt tuberculosis transmission by means of mass screening that was linked to treatment for active disease or latent infection.
METHODS: In a cluster-randomized study, we designated 15 clusters with 78,744 miners as either intervention clusters (40,981 miners in 8 clusters) or control clusters (37,763 miners in 7 clusters). In the intervention clusters, all miners were offered tuberculosis screening. If active tuberculosis was diagnosed, they were referred for treatment; if not, they were offered 9 months of isoniazid preventive therapy. The primary outcome was the cluster-level incidence of tuberculosis during the 12 months after the intervention ended. Secondary outcomes included tuberculosis prevalence at study completion.
RESULTS: In the intervention clusters, 27,126 miners (66.2%) underwent screening. Of these miners, 23,659 (87.2%) started taking isoniazid, and isoniazid was dispensed for 6 months or more to 35 to 79% of miners, depending on the cluster. The intervention did not reduce the incidence of tuberculosis, with rates of 3.02 per 100 person-years in the intervention clusters and 2.95 per 100 person-years in the control clusters (rate ratio in the intervention clusters, 1.00; 95% confidence interval [CI], 0.75 to 1.34; P=0.98; adjusted rate ratio, 0.96; 95% CI, 0.76 to 1.21; P=0.71), or the prevalence of tuberculosis (2.35% vs. 2.14%; adjusted prevalence ratio, 0.98; 95% CI, 0.65 to 1.48; P=0.90). Analysis of the direct effect of isoniazid in 10,909 miners showed a reduced incidence of tuberculosis during treatment (1.10 cases per 100 person-years among miners receiving isoniazid vs. 2.91 cases per 100 person-years among controls; adjusted rate ratio, 0.42; 95% CI, 0.20 to 0.88; P=0.03), but there was a subsequent rapid loss of protection.
CONCLUSIONS: Mass screening and treatment for latent tuberculosis had no significant effect on tuberculosis control in South African gold mines, despite the successful use of isoniazid in preventing tuberculosis during treatment. (Funded by the Consortium to Respond Effectively to the AIDS TB Epidemic and others; Thibela TB Current Controlled Trials number, ISRCTN63327174.).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24450889     DOI: 10.1056/NEJMoa1214289

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  86 in total

1.  Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study.

Authors:  Jonathan E Golub; Silvia Cohn; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Betina Durovni; Richard E Chaisson
Journal:  Clin Infect Dis       Date:  2014-11-02       Impact factor: 9.079

Review 2.  Update in Mycobacterium tuberculosis lung disease 2014.

Authors:  Paul Elkington; Alimuddin Zumla
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

3.  Age-specific prevalence of TB infection among household contacts of pulmonary TB: Is it time for TB preventive therapy?

Authors:  Chandra Kumar Dolla; Chandrasekaran Padmapriyadarsini; Kannan Thiruvengadam; Rahul Lokhande; Aarti Kinikar; Mandar Paradkar; Shrinivas Bm; Lakshmi Murali; Akshay Gupte; Sanjay Gaikwad; Sriram Selvaraju; Yashoda Padmanaban; Sathyamurthy Pattabiraman; Neeta Pradhan; Vandana Kulkarni; Shri Vijay Bala Yogendra Shivakumar; Munivardhan Prithivi; Anju Kagal; Barath Thopili Karthavarayan; Nishi Suryavanshi; Nikhil Gupte; Paul Kumaran; Vidya Mave; Amita Gupta
Journal:  Trans R Soc Trop Med Hyg       Date:  2019-10-11       Impact factor: 2.184

4.  Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model.

Authors:  David W Dowdy; Jonathan E Golub; Valeria Saraceni; Lawrence H Moulton; Solange C Cavalcante; Silvia Cohn; Antonio G Pacheco; Richard E Chaisson; Betina Durovni
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-15       Impact factor: 3.731

Review 5.  Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration.

Authors:  Nicole Salazar-Austin; David W Dowdy; Richard E Chaisson; Jonathan E Golub
Journal:  Am J Epidemiol       Date:  2019-12-31       Impact factor: 4.897

6.  Can treatment outcomes of latent TB infection and TB in silicosis be improved?

Authors:  Wing Wai Yew; Chi Chiu Leung; Kwok Chiu Chang; Ying Zhang; Denise P Chan
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

7.  Latent Tuberculosis in Health Care Workers Exposed to Active Tuberculosis in a Tertiary Care Hospital in Oman.

Authors:  Faryal Khamis; Adil Al-Lawati; Ibrahim Al-Zakwani; Seif Al-Abri; Jaleelah Al-Naamani; Harith Al-Harthi; Amina Al-Jardani; Aliya Al-Harthi
Journal:  Oman Med J       Date:  2016-07

Review 8.  Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection.

Authors:  Molebogeng X Rangaka; Solange C Cavalcante; Ben J Marais; Sok Thim; Neil A Martinson; Soumya Swaminathan; Richard E Chaisson
Journal:  Lancet       Date:  2015-10-26       Impact factor: 79.321

Review 9.  Transforming the fight against tuberculosis: targeting catalysts of transmission.

Authors:  David W Dowdy; Andrew S Azman; Emily A Kendall; Barun Mathema
Journal:  Clin Infect Dis       Date:  2014-06-30       Impact factor: 9.079

Review 10.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.